A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Stopped Inability to achieve and optimize a dose that could provide a positive benefit risk profile

Conditions

• KRAS Mutation-Related Tumors
• Metastatic Solid Tumor
• Advanced Solid Tumor

Interventions

• DRUG: TPX-0005
• DRUG: Trametinib

Sponsor

Turning Point Therapeutics, Inc.